BioSpace News Archive

Pharm Country

Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran

Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164 were on inclisiran)

August 30, 2020
·
11 min read
Policy

Statement from the Chief Public Health Officer of Canada on August 30, 2020

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

August 30, 2020
·
2 min read
Junshi Biosciences Announces Financial Results for Six Months Ended June 30, 2020 and Provides Corporate Updates

Expanding into infectious disease and collaborating with IMCAS and Lilly for COVID-19 neutralizing antibodies

August 30, 2020
·
9 min read
Drug Development

Innovent Announces the Results of the Phase 1/2 Clinical Study of PCSK9 Antibody Tafolecimab at the European Society of Cardiology Annual Conference

Innovent Biologics, Inc. announced that the Phase 1 and Phase 2 clinical study results of the recombinant fully human monoclonal antibody Tafolecimab were successfully presented in the 2020 European Society of Cardiology annual conference as e-Poster.

August 30, 2020
·
5 min read
Deals

GenScript Reports 2020 Interim Results and Provides Business Update

Company highlights revenue of non-cell therapy business doubled and its subsidiary Legend Biotech was listed on Nasdaq

August 30, 2020
·
11 min read
Drug Development

FARXIGA Demonstrated Unprecedented Reduction in the Risk of Kidney Failure and Cardiovascular or Renal Death in Patients with Chronic Kidney Disease in the Phase III DAPA-CKD Trial

FARXIGA is the first medicine to significantly prolong survival in a renal outcomes trial in patients with chronic kidney disease with and without type 2 diabetes

August 30, 2020
·
9 min read
Policy

CStone Receives US FDA IND Clearance for CS1001-201 Study to Evaluate Anti-PD-L1 Monoclonal Antibody Sugemalimab Monotherapy in R/R ENKTL

Extending the Global First Anti-PD-L1 Registration Clinical Study Targets for R/R ENKTL from China to the U.S.

August 30, 2020
·
6 min read